Newsmeme!
Discover News you didn't know existed

• home
• news
• tagging
• how it works
• about
• data

Ketoacidosis

News

New study data: JANUVIA (sitagliptin)

Published November 21, 2008, 6:31 am, EurekAlert!

( GCI Health ) New data presented at the 61st Annual Scientific Meeting of the Gerontological Society of America showed JANUVIA (sitagliptin), a diabetes medicine from Merck & Co. Inc., significantly reduced blood sugar levels in elderly patients with type 2 diabetes and was not associated with hypoglycemia (low blood sugar). In this study of 206 patients aged 65 to 96 years, there were no ...

Full Story

Tags

No tags found at this time. Be the first to tag this news item, learn more.

Imagery

Related Ketoacidosis Stories

From Various News Sources

New Study Data: JANUVIA? (sitagliptin) Significantly Reduced - MSN MoneyCentral
New data presented at the 61 st Annual Scientific Meeting of the Gerontological Society of America showed JANUVIA ? (sitagliptin), a diabetes medicine from Merck & Co., Inc., significantly reduced blood sugar levels in elderly patients with type 2 ...

New study data: JANUVIA (sitagliptin) - Genetic Engineering News
New data presented at the 61st Annual Scientific Meeting of the Gerontological Society of America showed JANUVIA (sitagliptin), a diabetes medicine from Merck & Co., Inc., significantly reduced blood sugar levels in elderly patients with type 2 ...

Merck says new data shows diabetes drug Januvia significantly reduces ... - RTT News
(RTTNews) - Merck & Co. Inc. (MRK: News ), a global research-driven pharmaceutical company, presenting a new data on Friday, said its diabetes drug Januvia, or sitagliptin, significantly reduced blood sugar levels in elderly patients with type-2 ...

FDA Approvals: Januvia CME/CE - Medscape News
October 19, 2006 ? The US Food and Drug Administration (FDA) has approved sitagliptin phosphate tablets for use with diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus. The once-daily agent can be used ...

Cardiovascular safety of vildagliptin, sitagliptin and others in the ... - PharmiWeb
The new oral antidiabetic drugs sitagliptin and vildagliptin work by boosting the guts incretin hormones GLP-1 and GIP to regulate insulin secretion following food intake and glucagon secretion when blood sugar is low. The new oral antidiabetic drugs ...

More proof needed on costly diabetes drugs - Reuters
CHICAGO (Reuters) - U.S. doctors are using a wider array of newer, more costly drugs to treat diabetes with little long-term proof that they work better than older, cheaper medications, U.S. researchers said on Monday. They said newer treatments ...

Expensive new diabetes drugs don't necessarily produce better outcomes - News-Medical.Net
The annual cost of prescription diabetes drugs nearly doubled to $12.5 billion between 2001 and 2007, according to a study by researchers at the Stanford University School of Medicine and the University of Chicago . The researchers say the findings ...

Since 2001 The Cost Of Diabetes Treatment Has Nearly Doubled - Medical News Today
Because of the increased number of patients, growing reliance on multiple medications and the shift toward more expensive new medicines, the annual cost of diabetes drugs nearly doubled in only six years, rising from $6.7 billion in 2001 to $12.5 ...

Are More Expensive Drugs Worth More and Better Than Older Generics? - Best Syndication
(Best Syndication News) More expensive diabetes drugs may not equate to better outcomes, according to new research from California and Illinois. While the cost of prescription diabetes drugs rose from $6.7 billion in 2001 to $12.5 in 2007, there were ...

Cost Of Diabetes Treatment Nearly Doubled - eMaxHealth.com
Because of the increased number of patients, growing reliance on multiple medications and the shift toward more expensive new medicines, the annual cost of diabetes drugs nearly doubled in only six years, rising from $6.7 billion in 2001 to $12.5 ...

Related Social Bookmarks

None found at this time.